RESUMEN
When the protein or calcium homeostasis of the endoplasmic reticulum (ER) is adversely altered, cells experience ER stress that leads to various diseases including neurodegeneration. Genetic deletion of an ER stress downstream effector, CHOP, significantly protects neuron somata and axons. Here we report that three tricyclic compounds identified through a small-scale high throughput screening using a CHOP promoter-driven luciferase cell-based assay, effectively inhibit ER stress by antagonizing their common target, histamine receptor H1 (HRH1). We further demonstrated that systemic administration of one of these compounds, maprotiline, or CRISPR-mediated retinal ganglion cell (RGC)-specific HRH1 inhibition, delivers considerable neuroprotection of both RGC somata and axons and preservation of visual function in two mouse optic neuropathy models. Finally, we determine that maprotiline restores ER homeostasis by inhibiting HRH1-mediated Ca2+ release from ER. In this work we establish maprotiline as a candidate neuroprotectant and HRH1 as a potential therapeutic target for glaucoma.
Asunto(s)
Maprotilina , Células Ganglionares de la Retina , Ratones , Animales , Células Ganglionares de la Retina/metabolismo , Maprotilina/metabolismo , Maprotilina/farmacología , Retículo Endoplásmico/metabolismo , Estrés del Retículo Endoplásmico , Modelos Animales de Enfermedad , Homeostasis , Receptores Histamínicos/metabolismoRESUMEN
Maprotiline is an antidepressant that has been found to cause hypoglycemia. However, the effect of maprotiline on diabetic nephropathy (DN) has not been investigated. Here, we explored the effect of maprotiline on human renal glomerular endothelial cells (HRGECs) in response to high glucose (HG) stimulation. We found that maprotiline attenuated HG-induced oxidative stress in HRGECs with decreased reactive oxygen species production and increased superoxide dismutase activity. Maprotiline repressed the HG-induced expression of cyclooxygenases 2 at both mRNA and protein levels in HRGECs. The increased thromboxane B2 level and decreased 6-keto-prostaglandin F1α level induced by HG were significantly attenuated by maprotiline treatment. Maprotiline also prevented the HG-induced increase in the permeability of HRGECs and the decrease in the zonula occludens-1 expression and downregulated HG-induced increase in the expression of protein kinase C-α (PKC-α) in HRGECs. This protective effect of maprotiline on HG-induced HRGECs dysfunction was abolished by overexpression of PKC-α. In conclusion, maprotiline displayed a protective effect on HG-challenged HRGECs, which was mediated by the regulation of PKC-α. These findings provide further evidence for the potential use of maprotiline for the treatment of DN.
Asunto(s)
Nefropatías Diabéticas , Células Endoteliales , Células Cultivadas , Nefropatías Diabéticas/metabolismo , Células Endoteliales/metabolismo , Glucosa/farmacología , Humanos , Glomérulos Renales/metabolismo , Maprotilina/metabolismo , Maprotilina/farmacología , Estrés Oxidativo , Prostaglandina-Endoperóxido Sintasas/metabolismo , Prostaglandina-Endoperóxido Sintasas/farmacología , Proteína Quinasa C-alfa/metabolismo , Proteína Quinasa C-alfa/farmacología , ARN Mensajero/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Superóxido Dismutasa/metabolismo , Superóxido Dismutasa/farmacología , Tromboxano B2/metabolismo , Tromboxano B2/farmacologíaRESUMEN
Selective norepinephrine reuptake inhibitors (sNRIs) provide an effective class of approved antipsychotics, whose inhibitory mechanism could facilitate the discovery of privileged scaffolds with enhanced drug efficacy. However, the crystal structure of human norepinephrine transporter (hNET) has not been determined yet and the inhibitory mechanism of sNRIs remains elusive. In this work, multiple computational methods were integrated to explore the inhibitory mechanism of approved sNRIs (atomoxetine, maprotiline, reboxetine and viloxazine), and 3 lines of evidences were provided to verify the calculation results. Consequently, a binding mode defined by interactions between three chemical moieties in sNRIs and eleven residues in hNET was identified as shared by approved sNRIs. In the meantime, binding modes of reboxetine's enantiomers with hNET were compared. 6 key residues favoring the binding of (S, S)-reboxetine over that of (R, R)-reboxetine were discovered. This is the first study reporting that those 11 residues are the common determinants for the binding of approved sNRIs. The identified binding mode shed light on the inhibitory mechanism of approved sNRIs, which could help identify novel scaffolds with improved drug efficacy.
Asunto(s)
Antipsicóticos/química , Simulación de Dinámica Molecular , Morfolinas/química , Inhibidores de la Captación de Neurotransmisores/química , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/química , Norepinefrina/química , Secuencias de Aminoácidos , Antipsicóticos/metabolismo , Clorhidrato de Atomoxetina/química , Clorhidrato de Atomoxetina/metabolismo , Sitios de Unión , Humanos , Maprotilina/química , Maprotilina/metabolismo , Simulación del Acoplamiento Molecular , Morfolinas/metabolismo , Inhibidores de la Captación de Neurotransmisores/metabolismo , Norepinefrina/metabolismo , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/antagonistas & inhibidores , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/metabolismo , Unión Proteica , Conformación Proteica en Hélice alfa , Conformación Proteica en Lámina beta , Dominios y Motivos de Interacción de Proteínas , Reboxetina , Estereoisomerismo , Homología Estructural de Proteína , Termodinámica , Viloxazina/química , Viloxazina/metabolismoRESUMEN
OBJECTIVE: To explore the site of action of maprotiline, as an atypical antidepressant, on carrageenan-induced paw edema. SUBJECTS: Male Wistar rats were used. METHODS: Firstly, the anti-inflammatory effect of systemic maprotiline (12.5, 25 and 50 mg kg(-1)) was assessed using a paw edema model. Secondly, different doses of maprotiline were administrated intracerebroventricularly, intrathecally and locally before carrageenan challenge. Finally, we tried to reverse the anti-inflammatory effect of maprotiline by propranolol (10 mg kg(-1)), prazosin (4 mg kg(-1)), yohimbine (10 mg kg(-1)), naloxone (4 mg kg(-1)) and mifepristone (5 mg kg(-1)). RESULTS: Systemic, intracerebroventricular and subplantar application of maprotiline significantly inhibited peripheral edema, but intrathecal maprotiline did not alter the degree of paw swelling. The applied antagonists failed to change the anti-inflammatory activity of maprotiline. CONCLUSION: These results demonstrate that maprotiline has a potent anti-inflammatory effect and this effect is linked to the peripheral and supraspinal actions of the drug.
Asunto(s)
Antiinflamatorios/uso terapéutico , Antidepresivos de Segunda Generación/uso terapéutico , Carragenina/farmacología , Edema , Maprotilina/uso terapéutico , Antagonistas de Receptores Adrenérgicos alfa 1/metabolismo , Antagonistas de Receptores Adrenérgicos alfa 2/metabolismo , Antagonistas Adrenérgicos beta/metabolismo , Animales , Antiinflamatorios/metabolismo , Antidepresivos de Segunda Generación/metabolismo , Edema/inducido químicamente , Edema/tratamiento farmacológico , Antagonistas de Hormonas/metabolismo , Indometacina/metabolismo , Indometacina/uso terapéutico , Inyecciones Espinales , Masculino , Maprotilina/metabolismo , Mifepristona/metabolismo , Naloxona/metabolismo , Antagonistas de Narcóticos/metabolismo , Prazosina/metabolismo , Propranolol/metabolismo , Ratas , Ratas Wistar , Yohimbina/metabolismoRESUMEN
Three potent antidepressants, (R)-nisoxetine, lortalamine, and oxaprotiline, with high affinity and high selectivity for the norepinephrine transporter (NET) were synthesized and radiolabeled with C-11 via [11C]methylation. The reference compounds and their corresponding normethyl precursors were synthesized via multi-step synthetic approaches. The radiochemical syntheses were performed by simple alkylation of the corresponding normethyl precursors with no-carrier-added [11C]CH3I in DMF. After HPLC purification, (R)-[N-11CH3]nisoxetine, [11C]lortalamine, and [11C]oxaprotiline were obtained in 63-97% radiochemical yields, whereas (R)-[O-11CH3]nisoxetine was obtained in 23-29% radiochemical yields due to substantial formation of the undesired N-[11C]methylated byproduct (64-70%). These C-11 labeled tracers allowed us to carry out comparative studies of NET in baboons with positron emission tomography (PET) and evaluate their potential as PET tracers for imaging brain NET.
Asunto(s)
Benzopiranos/síntesis química , Fluoxetina/análogos & derivados , Maprotilina/análogos & derivados , Papio , Tomografía de Emisión de Positrones , Simportadores/metabolismo , Animales , Benzopiranos/química , Benzopiranos/metabolismo , Radioisótopos de Carbono/química , Fluoxetina/síntesis química , Fluoxetina/química , Fluoxetina/metabolismo , Ligandos , Maprotilina/síntesis química , Maprotilina/química , Maprotilina/metabolismo , Estructura Molecular , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática , Estereoisomerismo , Simportadores/antagonistas & inhibidoresRESUMEN
From case reports of patients treated with the tetracyclic antidepressant drug maprotiline, it appears that this drug is subject to polymorphic metabolism. Thus, we studied formation of the major maprotiline metabolite desmethylmaprotiline to identify the human cytochrome P-450 enzymes (CYP) involved. In incubations with human liver microsomes from two different donors, the substrate maprotiline was used at five different concentrations (5 to 500 microM). For selective inhibition of CYPs, quinidine (0.5-50 microM; CYP2D6), furafylline (0.3-30 microM; CYP1A2), ketoconazole (0.2-20 microM; CYP3A4), mephenytoin (20-200 microM; CYP2C19), chlorzoxazone (1-100 microM; CYP2E1), sulphaphenazole (0.2-100 microM; CYP2C9) and coumarin (0.2-100 microM; CYP2A6) were used. Desmethylmaprotiline concentrations were measured by HPLC, and enzyme kinetic parameters were estimated using extended Michaelis-Menten equations with non-linear regression. Relevant inhibition of the desmethylmaprotiline formation rate was observed in incubations with quinidine, furafylline and ketoconazole only. Formation rates of desmethylmaprotiline were consistent with a two enzyme model with a high (K(M)=71 and 84 microM) and a low (K(M)=531 and 426 microM) affinity site for maprotiline in the two samples, respectively. The high affinity site was competitively inhibited by quinidine (K(i,nc) 0.13 and 0.61 microM), the low-affinity site was non-competitively inhibited by furafylline (K(i,nc) 0.11 and 1.3 microM). Thus it appears that CYP2D6 and CYPIA2 contribute to maprotiline demethylation. Based on the parameters obtained, for plasma concentrations of 1 microM 83% (mean) of desmethylmaprotiline formation in vivo is expected to be mediated by CYP2D6 while 17% only may be attributed to CYPIA2 activity.
Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Enzimas/metabolismo , Maprotilina/metabolismo , Microsomas Hepáticos/metabolismo , Teofilina/análogos & derivados , Células Cultivadas , Clorzoxazona/farmacología , Cumarinas/farmacología , Inhibidores Enzimáticos del Citocromo P-450 , Humanos , Cetoconazol/farmacología , Cinética , Maprotilina/química , Mefenitoína/farmacología , Microsomas Hepáticos/efectos de los fármacos , Modelos Biológicos , Quinidina/farmacología , Sulfafenazol/farmacología , Teofilina/farmacologíaRESUMEN
Hair samples of patients of psychiatry and hair samples of suicide cases were analysed by liquid-chromatography/ionspray-mass spectrometry (LC/MS) for antidepressants and neuroleptics. Electrospray ionisation (ESI) with in-source collision induced dissociation (ESI/CID) and tandem-mass spectrometry (MS/MS) were used for drug and metabolite identification. Mass spectra library searching was performed using an ESI/CID mass spectra library and a MS/MS spectra library. Furthermore, extracted ion chromatograms were used for the detection of N-desmethyl-metabolites, which were also identified by their fragment-ion spectra. Three examples using these methods are shown: The tricyclic antidepressant maprotiline, the selective serotonin receptor inhibitor (SSRI) citalopram and their desmethylmetabolites as well as the neuroleptic pipamperone were detected and identified in hair extracts. For extraction powdered hair was treated by ultrasonication in methanol and solid-phase extraction was used for sample clean-up prior to LC/MS or MS/MS analysis. These examples demonstrate the power of LC/MS and LC/MS/MS for the detection and identification of drugs in hair extracts using full-scan mode and ESI/CID with library searching or using highly selective LC/MS/MS-analysis with library searching or in multiple reaction monitoring mode.
Asunto(s)
Antidepresivos de Segunda Generación/análisis , Antipsicóticos/análisis , Autopsia/métodos , Butirofenonas/análisis , Cromatografía Liquida/métodos , Cromatografía de Gases y Espectrometría de Masas/métodos , Cabello/química , Maprotilina/análisis , Espectrometría de Masa de Ion Secundario/métodos , Detección de Abuso de Sustancias/métodos , Toxicología/métodos , Antidepresivos de Segunda Generación/química , Antidepresivos de Segunda Generación/metabolismo , Antipsicóticos/química , Antipsicóticos/metabolismo , Butirofenonas/química , Butirofenonas/metabolismo , Causas de Muerte , Bases de Datos Factuales , Humanos , Maprotilina/química , Maprotilina/metabolismo , SuicidioRESUMEN
(E)-N-(3-bromoprop-2-enyl)-2beta-carbomethoxy-3beta-4'-tolyl -nortropane or PE2Br, an analogue of cocaine was labelled with the positron emitter 76Br (T1/2=16 h) for pharmacological evaluation in the rat and PET investigation in the monkey. [76Br]PE2Br was obtained by electrophilic substitution from the tributylstannyl precursor with radiochemical yield of 80%. In vivo biodistribution studies of [76Br]PE2Br (20 MBq/nmol) in rats showed a high uptake in the striatum (2.2% ID/g tissue at 15 min p.i.). The striatum to cerebellum radioactivity ratio was 6 at 1 hour p.i. Striatal uptake of [76Br]PE2Br was almost completely prevented by pretreatment with GBR 12909, but citalopram and maprotiline had no effect, confirming the selectivity of the radioligand for the dopamine transporter. PET imaging of the biodistribution of [76Br]PE2Br in the baboon demonstrated rapid and high uptake in the brain (5% ID at 3 min p.i.). The striatal radioactivity concentration reached a plateau at 20 min p.i. (7% ID/100 mL). The uptake in the cortex and cerebellum was very low. A significantly higher uptake in the thalamus was observed. At 1h p.i., the striatum to cerebellum ratio and thalamus to cerebellum ratio were 8 and 1.9 respectively. In competition experiments the radioactivity in the striatum and the thalamus was displaced by 5 mg/kgof cocaine and 5 mg/kg of GBR 12909, but citalopram and maprotiline had no effect. These results showed that [76Br]PE2Br is in vivo a potent and selective radioligand suitable for PET imagingof the dopamine transporter.
Asunto(s)
Radioisótopos de Bromo , Dopamina/metabolismo , Nortropanos , Radiofármacos , Animales , Encéfalo/metabolismo , Cerebelo/metabolismo , Corteza Cerebral/metabolismo , Citalopram/metabolismo , Cocaína/metabolismo , Cuerpo Estriado/metabolismo , Cinética , Masculino , Maprotilina/metabolismo , Nortropanos/síntesis química , Nortropanos/farmacocinética , Papio/metabolismo , Piperazinas/metabolismo , Ratas , Ratas Wistar , Tálamo/metabolismo , Distribución Tisular , Tomografía Computarizada de EmisiónRESUMEN
Stedim 6 and Clearflex, two new polyethylene-lined materials for infusion bags, were studied for their compatibility with disodium clodronate, chlorpromazine and maprotiline hydrochlorides, diazepam, and clorazepate dipotassium salt, comparatively with borosilicate glass flasks and polyvinyl chloride bags. Diazepam, the only drug to exhibit a marked sorption in PVC bags (the loss reached 25% of the initial concentration after a contact duration of 72 h), showed lower sorption in Stedim 6 bags (loss about 11% under the same conditions) and none in Clearflex bags. No significant difference was observed between the infusion solutions used as vehicles of the drugs (5% dextrose and 0.9% sodium chloride isotonic solutions). The results are discussed in terms of lipophilicity of the drugs and crystallinity of the polymers.
Asunto(s)
Polietilenos/metabolismo , Cloruro de Polivinilo/metabolismo , Silicatos/metabolismo , Adsorción , Ansiolíticos/metabolismo , Antidepresivos Tricíclicos/metabolismo , Antipsicóticos/metabolismo , Clorpromazina/metabolismo , Ácido Clodrónico/metabolismo , Clorazepato Dipotásico/metabolismo , Diazepam/metabolismo , Vidrio , Bombas de Infusión , Maprotilina/metabolismo , Polietilenos/química , Cloruro de Polivinilo/química , Silicatos/química , Relación Estructura-ActividadRESUMEN
Inhibition of uptake 1 in the central nervous system leads to a decrease of sympathetic outflow to many tissues; central alpha 2-adrenoceptors are involved in this decrease. The aim of the present study was to compare the effects of the selective uptake 1 inhibitor (+)-oxaprotiline on the plasma kinetics of noradrenaline and adrenaline in anaesthetized and in conscious rabbits. [3H]Noradrenaline and [3H]adrenaline were infused i.v. The arterial plasma concentrations of endogenous and radiolabelled noradrenaline and adrenaline were measured, and the clearance from and spillover into the plasma of noradrenaline and adrenaline were calculated. Results obtained in conscious and anaesthetized rabbits were similar. (+)-Oxaprotiline 0.2, 0.6 and 1.8 mg kg-1 i.v. dose-dependently reduced the clearance of [3H]noradrenaline from the plasma. The clearance of [3H]adrenaline was reduced less. The spillover of endogenous noradrenaline was decreased by up to 35%. In contrast, the spillover of adrenaline tended to be enhanced. Prazosin 0.1 and 1 mg kg-1 was injected i.v. in a second part of each experiment. It lowered the blood pressure and caused a marked increase in noradrenaline spillover but no increase or even a decrease in adrenaline spillover. The results are compatible with the following hypothesis. The sympathetic outflow from the central nervous system is subject to a twofold alpha-adrenoceptor-mediated modulation: alpha 2-adrenoceptor-mediated inhibition and alpha 1-adrenoceptor-mediated excitation. In the control of the sympathetic outflow to many extra-adrenal tissues, the alpha 2-adrenergic inhibition prevails. Uptake 1 inhibitors depress sympathetic outflow to such tissues by enhancing the alpha 2-adrenergic inhibition.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Antidepresivos/antagonistas & inhibidores , Epinefrina/metabolismo , Maprotilina/análogos & derivados , Norepinefrina/metabolismo , Anestesia , Animales , Antidepresivos/metabolismo , Presión Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Epinefrina/sangre , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Cinética , Masculino , Maprotilina/antagonistas & inhibidores , Maprotilina/metabolismo , Norepinefrina/sangre , Prazosina/farmacología , Conejos , Receptores Adrenérgicos alfa 2/efectos de los fármacosRESUMEN
To investigate the pharmacokinetics and the disposition of levoprotiline after i.v. and p.o. administration and to assess the absolute bioavailability, 12 healthy volunteers (11 women, 1 man) were given a 10 min i.v. infusion of 15 mg and a p.o. dose of 75 mg in a two-way crossover study. Blood and urine samples were collected after each dose. Unchanged levoprotiline and the sum of unchanged and glucuronidated levoprotiline (= total levoprotiline) were determined by a specific gas chromatographic-mass spectro-metric method. Intravenous levoprotiline was rapidly and extensively distributed into extravascular sites of the body; the steady-state volume of distribution was 18.81 kg-1. The elimination of levoprotiline from blood was independent of the dosing route, the half-life being 18.8 h. Only 1.8 and 0.6 per cent of the i.v. and p.o. dose, respectively, were excreted unchanged in the urine, whereas 57 per cent of each dose were renally excreted as total levoprotiline. The absolute bioavailability of p.o. levoprotiline was 40 per cent. About 60 per cent of the dose was subject to a first-pass effect in the liver. The systemic blood clearance of levoprotiline, determined after i.v. dosing, was 885 ml min-1, the renal blood clearance after i.v. and p.o. dosing was only 16.0 and 14.2 ml min-1, respectively. Presystemic and systemic clearance of levoprotiline occurred predominantly by direct glucuronidation.
Asunto(s)
Antidepresivos/farmacocinética , Maprotilina/análogos & derivados , Administración Oral , Adulto , Antidepresivos/administración & dosificación , Disponibilidad Biológica , Biotransformación , Femenino , Semivida , Humanos , Inyecciones Intravenosas , Masculino , Maprotilina/administración & dosificación , Maprotilina/metabolismo , Maprotilina/farmacocinéticaRESUMEN
The uptake sites for norepinephrine (NE) in brain have not been studied in much detail, probably due to the absence of an adequate radioligand for labeling these sites. This study describes the binding properties of [3H]nisoxetine to uptake sites for NE in rat brain homogenates and in tissue slices analyzed by quantitative autoradiography. The binding of [3H]nisoxetine was found to be saturable and sodium-dependent to a single class of binding sites (Kd = 0.8 nM). The potencies of drugs to inhibit the uptake of NE correlated highly with their potencies to inhibit the binding of [3H]nisoxetine. Studies using [3H]nisoxetine for mapping of sites associated with uptake of NE by quantitative autoradiography indicated that the pattern of binding of [3H] nisoxetine is consistent with the pattern of noradrenergic innervation. Destruction of central noradrenergic neurons by 6-OH-dopamine or DSP-4 resulted in large decreases in the binding of [3H]nisoxetine in almost all areas of the brain regions examined. [3H]Nisoxetine should prove to be a useful tool to study the regulation of uptake sites for NE as well as a useful marker for noradrenergic innervation in the study of various neurological diseases.
Asunto(s)
Encéfalo/metabolismo , Fluoxetina/análogos & derivados , Norepinefrina/metabolismo , 5,7-Dihidroxitriptamina/farmacología , Animales , Autorradiografía , Unión Competitiva , Corteza Cerebral/metabolismo , Fluoxetina/metabolismo , Cinética , Masculino , Maprotilina/análogos & derivados , Maprotilina/metabolismo , Norepinefrina/farmacología , Oxidopamina/farmacología , Ensayo de Unión Radioligante , Ratas , Ratas Endogámicas , Estereoisomerismo , TritioRESUMEN
The behavioural and biochemical effects of repeated (14 and 28 days) treatment with (+)-oxaprotiline (a noradrenaline uptake inhibitor) and (-)-oxaprotiline (levoprotiline, without influence on noradrenaline uptake; the clinically active antidepressant) were studied in rats. Both those enantiomers given repeatedly increased the locomotor and exploratory activity and reduced the immobility time in Porsolt's test. The D-amphetamine-induced locomotor hyperactivity, as well as the stereotypies induced by D-amphetamine and apomorphine, were increased by the oxaprotilines. Single-dose treatment with both the oxaprotilines was not effective in the tests mentioned above. Repeated (+)-oxaprotiline administration reduced the binding (Bmax but not KD) to dopamine D-1 receptors in the striatum and limbic system; levoprotiline was inactive. The binding to dopamine D-2 receptors was not changed by either drug. Both the enantiomers showed only low affinity for brain dopamine D-1 and D-2 receptors in vitro. The obtained results indicate that chronic treatment with (+)- and (-)-oxaprotiline increases behavioural responsiveness of the dopamine mesolimbic and striatal systems.
Asunto(s)
Antidepresivos/farmacología , Maprotilina/análogos & derivados , Receptores Dopaminérgicos/efectos de los fármacos , Animales , Antidepresivos/metabolismo , Apomorfina/farmacología , Benzazepinas/farmacología , Dextroanfetamina/farmacología , Conducta Exploratoria/efectos de los fármacos , Masculino , Maprotilina/metabolismo , Maprotilina/farmacología , Actividad Motora/efectos de los fármacos , Ratas , Ratas Endogámicas , Espiperona/farmacología , Estereoisomerismo , Conducta Estereotipada/efectos de los fármacos , NataciónRESUMEN
Blood levels of Maprotiline were analysed and their relationship to the clinical response was examined in 89 depressed inpatients, according DSM III criteria for Major Depressive Episode, given the drug treatment for 3 weeks. Maprotiline produced marked decreases in mean MADRS and COVI scale scores by the end of treatment. On day 21, no correlation between blood levels of Maprotiline and MADRS or COVI scores were found when all patients were considered. Nevertheless, significant correlations were observed on day 14 (r = .22; p less than .05 for MADRS and r = .23; p less than .05 for COVI scale). In addition, a significant correlation between MADRS or COVI scale scores and Maprotiline blood levels were observed on days 14 and 21 in subgroups of young patients, severe depression (high scores to clinical global investigations), during of at least 3 months, treated without other drug than Maprotiline and good responders.
Asunto(s)
Antracenos/sangre , Trastorno Depresivo/sangre , Maprotilina/sangre , Adulto , Anciano , Ensayos Clínicos como Asunto , Trastorno Depresivo/tratamiento farmacológico , Femenino , Humanos , Masculino , Maprotilina/metabolismo , Maprotilina/uso terapéutico , Persona de Mediana Edad , Estadística como AsuntoRESUMEN
The S- and F-forms of alpha-1 acid glycoprotein (AAG) variants have been isolated by isoelectric focusing with immobilines from commercially available AAG. In equilibrium dialysis experiments using a multicompartmental system, a higher affinity for various basic drugs has been found with S- in comparison with F-AAG: Amitriptyline, nortriptyline, imipramine, desipramine, trimipramine, methadone, thioridazine, clomipramine, desmethylclomipramine, and maprotiline. The selectivity (binding to S- vs. F-AAG) is the most pronounced for methadone and the lowest for thioridazine, while it is absent for the acidic drug mephenytoin.
Asunto(s)
Orosomucoide/metabolismo , Psicotrópicos/metabolismo , Amitriptilina/metabolismo , Clomipramina/metabolismo , Desipramina/metabolismo , Concentración de Iones de Hidrógeno , Imipramina/metabolismo , Maprotilina/metabolismo , Metadona/metabolismo , Orosomucoide/análogos & derivados , Tioridazina/metabolismo , Trimipramina/metabolismoRESUMEN
A gas chromatographic/mass spectrometric method (using either electron impact or chemical ionisation with methane or ammonia) is described for the quantitative analysis of maprotiline (MP, Ludiomil), N-acetylmaprotiline (AcMP) and N-acetyldesmethylmaprotiline (AcDMP) in whole blood or plasma. In two groups (A and B) of 82 and 53 depressive patients treated clinically with MP for 10 and 21 days, respectively, plasma and whole blood MP was monitored during the treatment. In group A, all subjects were phenotyped with debrisoquine and mephenytoin, and 44 with sulfamidine. 5 patients were poor metabolizers of debrisoquine and 2 of mephenytoin; 18 subjects were fast acetylators of sulfamidine. Traces of AcMP were found only in two patients. AcDMP was present in levels below 2 ng/ml in the plasma of most of the patients in group A. In group B, AcDMP levels between 2.4-14.6 ng/ml of whole blood were found in 9 patients. The mass spectral data suggest the presence of another, unknown MP metabolite interfering partly with the analysis of AcDMP. The presence of AcDMP seemed not to be related to the phenotype of the patients as determined by the pharmacogenetic tests.
Asunto(s)
Antracenos/metabolismo , Trastorno Depresivo/metabolismo , Maprotilina/metabolismo , Acetilación , Debrisoquina , Cromatografía de Gases y Espectrometría de Masas , Humanos , Maprotilina/análogos & derivados , Mefenitoína , Fenotipo , SulfametazinaRESUMEN
In a double-blind, controlled, cross-over trial on 10 healthy volunteers, the effects of daily doses of maprotiline (75 mg) and zimelidine (100 mg) over a 14-day period were tested on saliva secretion rate and saliva composition. Based on current knowledge of salivary gland physiology and the difference in specificity between the two drugs, differences in salivary gland response could be expected. Since both drugs have anticholinergic effects which influence saliva secretion rate, the measured component concentrations had to be recalculated with regard to dependencies of secretion rate. Maprotiline, but not zimelidine, caused strong inhibition of secretion rate and accommodation ability. Maprotiline consistently caused around 50% increases in concentrations of the following saliva components: protein, amylase, fucose, hexose, sialic acid and potassium. The effects of zimelidine were less pronounced and resulted in initial increases of most organic components. 14 and 18 h after the intake of the drug these increases had disappeared and some of the components instead showed decreased concentrations. The results are consistent with current theories about facilitated serotoninergic and noradrenergic transmissions during treatment with antidepressants.
Asunto(s)
Antracenos/farmacología , Maprotilina/farmacología , Saliva/metabolismo , Zimeldina/farmacología , Absorción , Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Femenino , Humanos , Masculino , Maprotilina/metabolismo , Saliva/análisis , Saliva/efectos de los fármacos , Factores de Tiempo , Zimeldina/metabolismoRESUMEN
The biotransformation of oxaprotiline has been investigated in rat and dog after oral administration of racemic 14C-labelled oxaprotiline X HCl. Rats excreted 28% dose in urine within 120 h and dogs 32% within 96 h. The metabolites were isolated by liquid chromatography and their structures elucidated by spectroscopic methods. In both species, oxaprotiline is extensively metabolized. Principal metabolic transformations are aromatic hydroxylations and formation of aromatic hydroxy-methoxy derivatives, N-demethylation, deamination and direct O-glucuronidation. Most of the primary metabolites formed by functionalization reactions occur in both free and glucuronidated form. In the rat, diastereoisomeric 3-hydroxy metabolites and the corresponding phenolic glucuronides are predominant. Products of deamination are minor, and products of direct O-glucuronidation are not detectable. In the dog, biotransformation is more complex. Major metabolites are diastereoisomeric 2- and 3-hydroxy compounds and the corresponding phenolic glucuronides. Oxidations in the side-chain and direct O-glucuronidation are minor metabolic pathways.
Asunto(s)
Antracenos/metabolismo , Maprotilina/metabolismo , Animales , Biotransformación , Perros , Espectroscopía de Resonancia Magnética , Maprotilina/análogos & derivados , Maprotilina/orina , Espectrometría de Masas , RatasRESUMEN
A case is reported of self-poisoning with maprotiline followed by prolonged disorders of intraventricular conduction. The cardiotoxicity of tetracyclic antidepressants was well established, but few cases were reported. Maprotiline pharmacokinetics explained the duration of the cardiovascular side-effects. The severity of maprotiline overdoses should not be underestimated.